Fig. 3From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 studyOverall survival curves for 76 patients with detectable mutation. Data are categorized according to whether mutation was in panel ET*. *Panel ET: epigenetic modifier-related or transcription factor-related gene mutations, but without FLT3-ITD co-mutationBack to article page